PIK3CA and cancer: Our finding that Black patients with PIK3CA alterations were less likely to be enrolled in clinical trials compared with White patients is aligned with public health data that Black patients are underrepresented in cancer clinical trials.8,9,10,11,12,53,54,55,56,57,58 This is an area of increasing concern within oncology, and efforts to diversify clinical trials must continue, including ongoing research to identify barriers, promoters, and solutions for equitable clinical trial participation.10,53,59,60,61,62,63,64